Highlights of Vitreoretina

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  17 (2024)
Volume  16 (2023)
Volume  15 (2022)
Volume  14 (2021)
Volume  13 (2020)
Volume  12 (2019)
Volume  11 (2018)
Volume  10 (2017)
Volume  9 (2016)
Volume  8 (2015)
Volume  7 (2014)
Volume  6 (2013)
Volume  5 (2012)
Volume  2 (2010)
Related articles

VOLUME 15 , ISSUE 4 ( December, 2022 ) > List of Articles

Coriorretinopatía Serosa Central (CRSC)

Mario Gutiérrez Paz, Hector Quintanilla, Carlos Estrada-Reyes

Keywords : Coriorretinopatía serosa central, anti-VEGF, Esplerone, Espironolactona, Terapia Fotodinámica, Láser de micropulso, TCO, Autofluorescencia, Angiografia

Citation Information : Paz MG, Quintanilla H, Estrada-Reyes C. Coriorretinopatía Serosa Central (CRSC). 2022; 15 (4):12-21.

DOI: 10.5005/hov-10102-15402

Published Online: 02-12-2022

Copyright Statement:  Copyright © 2022; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

La coriorretinopatía serosa central (CRSC) es una causa común de pérdida de visión central, que afecta principalmente a los hombres de 20 a 60 años. El objetivo de esta revisión es proporcionar una variedad de intervenciones disponibles para tratar la CRSC, incluida la observación, farmacología, Anti-VEGF, el tratamiento con láser y la terapia fotodinámica. Se ha descrito que muchas estrategias de tratamiento, como la terapia fotodinámica con verteporfina, y el tratamiento con láser de micropulso, son eficaces. Sin embargo, la evidencia disponible sugiere que la terapia fotodinámica de media dosis (o media fluida) debe ser el tratamiento de elección en la CRSC crónica, mientras que la observación puede ser el enfoque preferido en la CRSC aguda.

PDF Share
  1. Gass JD: Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967; 63(suppl):1–139.
  2. Wang M, Munch IC, Hasler PW, Prunte C, Larsen M: Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126–145.
  3. Lai WY, Tseng CL, Wu TT, Lin HS, Sheu SJ. Correlation between baseline retinal microstructures in spectral-domain optic coherence tomography and need for early intervention in central serous chorioretinopathy. BMJ Open Ophthalmol. 2017 Aug 16;2(1):e000054.
  4. Breukink MB, Dingemans AJ, den Hollander AI, Keunen JE, MacLaren RE, Fauser S, Querques G, Hoyng CB, Downes SM, Boon CJ. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol. 2016 Dec 20;11:39-46.
  5. Lai WY, Tseng CL, Wu TT, Lin HS, Sheu SJ. Correlation between baseline retinal microstructures in spectral-domain optic coherence tomography and need for early intervention in central serous chorioretinopathy. BMJ Open Ophthalmol. 2017 Aug 16;2(1):e000054.
  6. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015 Sep;48:82-118 propuso.
  7. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103:2070Y2079.
  8. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019 Jan;33(1):14-33.
  9. Spaide RF, Goldbaum M, Wong DW, et al. Serous detachment of the retina. Retina. 2003;23:820Y846.
  10. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography guided photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23:288Y298.
  11. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous retinopathy. Retina. 2003;23:752Y763.
  12. Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23:1Y7.
  13. Levine R, Brucker AJ, Robinson F. Long term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96:854Y859.
  14. Liu B, Deng T, Zhang J. RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis. Retina. 2016 Jan;36(1):9-19.
  15. Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, Gomi F, Koh AH, Lee WK, Wong TY. Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology. 2018 May;125(5):708-724.
  16. Bagheri M, Rashe Z, Ahoor MH, Somi MH. Prevalence of Helicobacter pylori Infection in Patients with Central Serous Chorioretinopathy: A Review. Med Hypothesis Discov Innov Ophthalmol. 2017 Winter;6(4):118-124. PMID: 29560365; PMCID: PMC5847306.
  17. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015 Sep;48:82-118.
  18. Birnbaum AD, Blair MP, Tessler HH, Goldstein DA. Subretinal fluid in acute posterior multifocal placoid pigment epitheliopathy. Retina. 2010 May;30(5):810-4.
  19. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine-green video angiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112:1057Y1062.
  20. Gomolin JE. Choroidal neovascularization and central serous chorioretinopathy. Can J Ophthalmol. 1989;24(1):20-23.
  21. Loo RH, Scott IU, Flynn HW Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22(1):19-24.
  22. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103(12):2070-2079.
  23. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015 Sep;48:82-118.
  24. Montero JA, Ruiz-Moreno JM Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy British Journal of Ophthalmology 2005;89:562-564.
  25. Hata M, Oishi A, Shimozono M, Mandai M, Nishida A, Kurimoto Y. Early changes in foveal thickness in eyes with central serous chorioretinopathy. Retina. 2013 Feb;33(2):296-301.
  26. Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol 2009;148:105–110 e101.
  27. Furuta M, Iida T, Kishi S. Foveal thickness can predict visual outcome in patients with persistent central serous chorioretinopathy. Ophthalmologica 2009;223:28–31.
  28. Matsumoto H, Kishi S, Otani T, Sato T. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol. 2008 Jan;145(1):162-168.
  29. Yu J, Jiang C, Xu G. CORRELATIONS BETWEEN CHANGES IN PHOTORECEPTOR LAYER AND OTHER CLINICAL CHARACTERISTICS IN CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2019 Jun;39(6):1110-1116.
  30. Yang, L. H., Jonas, J. B. & Wei, W. B. Optical Coherence Tomography–Assisted Enhanced Depth Imaging of Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci. 54, 4659–4665 (2013).
  31. Ozdemir I, Eren A, Ersöz G. Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy. Int Ophthalmol. 2019 Jun;39(6):1323-1328.
  32. Hamzah F, Shinojima A, Mori R, Yuzawa M. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy. BMC Ophthalmol. 2014 Nov 25;14:145.
  33. Pang CE, Freund KB. Pachychoroid neovas- culopathy. Retina. 2015;35(1):1-9.
  34. Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, et al. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014;3(4):111-115.
  35. Weinberger AW, Lappas A, Kirschkamp T, et al. Fundus near infrared fluorescence correlates with fundus near infrared reflectance. Invest Ophthalmol Vis Sci 2006;47:3098–3108.
  36. Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. 2015 Nov;253(11):1889-97.
  37. Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005;112:825–833.
  38. Han J, Cho NS, Kim K, Kim ES, Kim DG, Kim JM, Yu SY. FUNDUS AUTOFLUORESCENCE PATTERNS IN CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2020 Jul;40(7):1387-1394.
  39. Matsumoto H, Kishi S, Sato T, Mukai R. Fundus autofluorescence of elongated photoreceptor outer segments in central serous chorioretinopathy. Am J Ophthalmol. 2011 Apr;151(4):617-623.e1.
  40. Levine R, Brucker AJ, Robinson F. Long-Term Follow-up of Idiopathic Central Serous Chorioretinopathy by Fluorescein Angiography. Ophthalmology 1989;96:854- 9.
  41. Yamada K, Hayasaka S, Setogawa T. Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit. Ophthalmologica. 1992;205(2):69-76.
  42. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994 Aug;112(8):1057-62.
  43. Amada K, Hayasaka S, Setogawa T. Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit. Ophthalmologica. 1992;205(2):69-76.
  44. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231-42.
  45. Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203-13.
  46. Jia Y, Bailey ST, Wilson DJ, et al. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related maculardegeneration. Ophthalmology. 2014;121(7):1435.
  47. Chan SY, Wang Q, Wei WB, Jonas JB. OPTICAL COHERENCE TOMOGRAPHIC ANGIOGRAPHY IN CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2016 Nov;36(11):2051-2058.
  48. Bonini Filho MA, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK. Association of Choroidal Neovascularization and Central Serous Chorioretinopathy With Optical Coherence Tomography Angiography. JAMA Ophthalmol. 2015 Aug;133(8):899-906.
  49. Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. Retina. 2019 May;39(5):980-987.
  50. Liegl R, Ulbig M, W: Central Serous Chorioretinopathy. Ophthalmologica 2014;232:65-76.
  51. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010 Dec;24(12):1743-56.
  52. Gomolin JE. Choroidal neovascularization andcentral serous chorioretinopathy. Can J Ophthalmol. 1989;24(1):20-23.
  53. Loo RH, Scott IU, Flynn HW Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22(1):19-24.
  54. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103(12):2070-2079.
  55. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res. 2010 Feb;35(2):91-8. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res. 2010 Feb;35(2):91-8.
  56. Kim M, Lee SC, Lee SJ. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013;229(3):152-7. doi: 10.1159/000345495. Epub 2012 Dec 14. PMID: 23257663.
  57. Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011 Nov;152(5):784-92.e2.
  58. Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology. 2014 Feb;121(2):558-65.
  59. Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015 Jun;99(6):848-52.
  60. Chhablani J, Kozak I, Pichi F, Chenworth M, Berrocal MH, Bedi R, Singh RP, Wu L, Meyerle C, Casella AM, Mansour A, Bashshur Z, Scorza A, Carrai P, Nucci P, Arevalo JF; King Khaled Eye Specialist Hospital International Collaborative Retina Study Group. OUTCOMES OF TREATMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CENTRAL SEROUS CHORIORETINOPATHY WITH INTRAVITREAL ANTIANGIOGENIC AGENTS. Retina. 2015 Dec;35(12):2489-97.
  61. Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG; MINERVA study group. EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study. Retina. 2018 Aug;38(8):1464-1477.
  62. Balaratnasingam C, Bailey K, Tan A, et al. Bullous variant of central serous chorioretinopathy: expansion of phenotypic features using multimethod imaging. Ophthalmology 2016;123:1541–1552.
  63. Otzuka S, Ohba N, Nakao K. A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina 2002;22:25–32.
  64. Bousquet E, Beydoun T, Rothschild PR, Bergin C, Zhao M, Batista R, Brandely ML, Couraud B, Farman N, Gaudric A, Chast F, Behar-Cohen F. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. Retina. 2015 Dec;35(12):2505-15.
  65. van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF. Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial. Am J Ophthalmol. 2022 Jan;233:101-110.
  66. Liew G, Ho IV, Ong S, Gopinath B, Mitchell P. Efficacy of Topical Carbonic Anhydrase Inhibitors in Reducing Duration of Chronic Central Serous Chorioretinopathy. Transl Vis Sci Technol. 2020 Dec 4;9(13):6.
  67. T. Scholz P, Altay L, Fauser S. A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders. Adv Ther. 2017 Jul;34(7):1528-1555.
  68. Sousa K, Calvão-Santos G, João M, Gomes N, Falcão M. 532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy. Clinic.
  69. Scholz P, Altay L, Fauser S. A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders. Adv Ther. 2017 Jul;34(7):1528-1555.
  70. Joondeph BC, Joondeph HC, Blair NP. Retinal macroaneurysms treated with the yellow dye laser. Retina. 1989;9:187–192.
  71. Scholz P, Altay L, Fauser S. A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders. Adv Ther. 2017 Jul;34(7):1528-1555.
  72. Sousa K, Calvão-Santos G, João M, Gomes N, Falcão M. 532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy. Clin Ophthalmol. 2020 Feb 25;14:525-531.
  73. Arora S, Sridharan P, Arora T, Chhabra M, Ghosh B. Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy. Clin Exp Optom. 2019;102(1):79–85.
  74. Maruko I, Koizumi H, Hasegawa T, Arakawa H, Iida T. Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy. PLoS One. 2017 Aug 29;12(8):e0184112.
  75. Scholz P, Ersoy L, Boon CJ, Fauser S. Subthreshold Micropulse Laser (577 nm) Treatment in Chronic Central Serous Chorioretinopathy. Ophthalmologica. 2015;234(4):189-94.
  76. Roca JA, Wu L, Fromow-Guerra J, Rodríguez FJ, Berrocal MH, Rojas S, Lima LH, Gallego-Pinazo R, Chhablani J, Arevalo JF, Lozano-Rechy D, Serrano M. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol. 2018 Dec;102(12):1696-1700.
  77. Long, H., Liu, M., Hu, Q. et al. 577 nm subthreshold micropulse laser treatment for acute central serous chorioretinopathy: a comparative study. BMC Ophthalmol 22, 105 (2022).
  78. Russo A, Turano R, Morescalchi F, Gambicorti E, Cancarini A, Duse S, Costagliola C, Semeraro F. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1141-1148.
  79. Cheng CK, Chang CK, Peng CH. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2017 Feb;37(2):325-333.
  80. Cheng CK, Chang CK, Peng CH. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2017 Feb;37(2):325-333.
  81. Iacono P, Da Pozzo S, Varano M, Parravano M. Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy. Pharmaceuticals (Basel). 2020 Oct 29;13(11):349.
  82. Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan CT, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015 Mar;133(3):333-40.
  83. Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy. Am J Ophthalmol. 2016 Jul;167:57-64.
  84. van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. 2018 Oct;125(10):1547-1555.
  85. van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, MacLaren RE, Downes SM, Fauser S, Boon CJF, Hoyng CB. Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial. Am J Ophthalmol. 2020 Aug;216:80-89.
  86. Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. Retina. 2019 May;39(5):980-987.
  87. Teussink MM, Breukink MB, van Grinsven MJ, Hoyng CB, Klevering BJ, Boon CJ, de Jong EK, Theelen T. OCT Angiography Compared to Fluorescein and Indocyanine Green Angiography in Chronic Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5229-37.
  88. Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Gregório T, Cachulo ML, Pires IA, Cunha-Vaz JG, Murta JN. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013 Feb;33(2):309-15.
  89. van Dijk EHC, Dijkman G, Boon CJF. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. Graefes Arch Clin Exp Ophthalmol. 2017 Oct;255(10):2029-2035.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.